News
CCCC
3.300
-2.65%
-0.090
Weekly Report: what happened at CCCC last week (0914-0918)?
Weekly Report · 22h ago
Weekly Report: what happened at CCCC last week (0907-0911)?
Weekly Report · 09/14 10:01
Weekly Report: what happened at CCCC last week (0831-0904)?
Weekly Report · 09/07 09:56
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts
Seeking Alpha · 09/05 07:54
C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting
Benzinga · 09/03 11:10
Weekly Report: what happened at CCCC last week (0824-0828)?
Weekly Report · 08/31 10:01
Weekly Report: what happened at CCCC last week (0817-0821)?
Weekly Report · 08/24 10:01
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
NASDAQ · 08/21 16:00
Weekly Report: what happened at CCCC last week (0810-0814)?
Weekly Report · 08/17 10:02
Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St · 08/14 12:03
C4 Therapeutics Narrows Loss In Q2; Phase 2 Trial's ORR Data Due In H2 FY27
NASDAQ · 08/13 15:13
Wells Fargo Releases a Buy Rating on C4 Therapeutics (CCCC)
TipRanks · 08/12 10:58
Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Codexis (CDXS) and LENZ Therapeutics (LENZ)
TipRanks · 08/12 05:20
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 08/11 12:15
C4 Therapeutics reports Q2 EPS (18c), consensus (23c)
TipRanks · 08/11 11:10
*C4 Therapeutics 2Q Loss/Shr 18c >CCCC
Dow Jones · 08/11 11:00
Weekly Report: what happened at CCCC last week (0803-0807)?
Weekly Report · 08/10 09:58
C4 Therapeutics Reports Tomorrow With Shrinking Revenue Forecasts Already Priced In—Or Not
Barchart · 08/05 16:05
Weekly Report: what happened at CCCC last week (0727-0731)?
Weekly Report · 08/03 09:58
Weekly Report: what happened at CCCC last week (0720-0724)?
Weekly Report · 07/27 10:01
More
Webull provides a variety of real-time CCCC stock news. You can receive the latest news about C4 Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).